Additional file 2 Searched Papers Containing pm in Title/Abstract 2012


Download 0.55 Mb.
Size0.55 Mb.
  1   2   3   4   5   6   7   8   9   ...   12
Additional file 2 Searched Papers Containing PM in Title/Abstract 2012

  1. Abbate R, Cioni G, Marcucci R, Fatini C, Gensini GF. [Antithrombotic drugs in women: should we worry more about bleeding?]. G Ital Cardiol (Rome). 2012 Jun;13(6):407-13. doi: 10.1714/1073.11758. Italian.

  2. Agúndez JA, Del Barrio J, Padró T, Stephens C, Farré M, Andrade RJ, Badimon L, García-Martín E, Vilahur G, Lucena MI. Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Front Pharmacol. 2012;3:2.

  3. Agarwal A. Do companion diagnostics make economic sense for drug developers? N Biotechnol. 2012 May 1.

  4. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012 Jun;11(8):593-5.

  5. Allen TC. State pathology societies and the future of pathology. Arch Pathol Lab Med. 2012 Feb;136(2):139.

  6. Álvarez P, Marchal JA, Boulaiz H, Carrillo E, Vélez C, Rodríguez-Serrano F, Melguizo C, Prados J, Madeddu R, Aranega A. 5-Fluorouracil derivatives: a patent review. Expert Opin Ther Pat. 2012 Feb;22(2):107-23. NO ACCESS
  7. Amaria RN, Lewis KD, Jimeno A. Vemurafenib: the road to personalized medicine in melanoma. Drugs Today (Barc). 2012 Feb;48(2):109-18. Review. NO ACCESS

  8. Amstad E, Reimhult E. Nanoparticle actuated hollow drug delivery vehicles. Nanomedicine (Lond). 2012 Jan;7(1):145-64. Review.

  9. Anderson ER, Burmester JK, Caldwell MD. Evaluation of a Mitochondrial DANN Mutation in Maternally Inherited and Sporadic Cases of Dupuytren's Disease. Clin Med Res. 2012 May 25. NO ACCESS

  10. Andoh A. Recent approaches of personalized medicine for inflammatory bowel disease. Nihon Shokakibyo Gakkai Zasshi. 2012 Mar;109(3):355-63. NO ACCESS

  11. Andre F, Nowak F, Arnedos M, Lacroix L, Viens P, Calvo F. Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res. 2012 Mar 15;18(6):1555-60.

  12. Ansari D, Chen BC, Dong L, Zhou MT, Andersson R. Pancreatic cancer: translational research aspects and clinical implications. World J Gastroenterol. 2012 Apr 7;18(13):1417-24.

  13. Ardini E, Galvani A. ALK Inhibitors, a Pharmaceutical Perspective. Front Oncol. 2012;2:17.

  14. Arnedos M, André F, Farace F, Lacroix L, Besse B, Robert C, Soria JC, Eggermont AM. The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. Mol Oncol. 2012 Apr;6(2):204-10. NO ACCESS

  15. Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant.2012 Jul;47(7):881-94. doi: 10.1038/bmt.2011.146.
  16. Audenet F, Yates DR, Cancel-Tassin G, Cussenot O, Rouprêt M. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int. 2012 Jun;109(12):1864-70. doi: 10.1111/j.1464-410X.2011.10661.x.

  17. Aurand TC, Russell MS, March JC. Synthetic signaling networks for therapeutic applications. Curr Opin Biotechnol. 2012 Jan 27.

  18. Ausborn NL, Le QT, Bradley JD, Choy H, Dicker AP, Saha D, Simko J, Story MD, Torossian A, Lu B. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e453-64.

  19. Aw W, Lezhava A, Andoh A, Tanaka H, Hayashizaki Y, Ishikawa T. The SmartAmp method: Rapid Detection of SNPs in Thiopurine S-Methyltransferase and ABC Transporters ABCC4 and ABCG2. Curr Drug Metab. 2012 May 16. NO ACCESS

  20. Ballestrero A, Garuti A, Cirmena G, Rocco I, Palermo C, Nencioni A, Scabini S, Zoppoli G, Parodi S, Patrone F. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets. 2012 May;12(4):316-28. NO ACCESS

  21. Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, Godfrey TE, Litle VR. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg. 2012 Apr;93(4):1101-6.

  22. Bartlett G, Zgheib N, Manamperi A, Wang W, Hizel C, Kahveci R, Yazan Y. Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine? Curr Pharmacogenomics Person Med. 2012;10(2):101-105.

  23. Barzegari A, Saei AA. Designing probiotics with respect to the native microbiome. Future Microbiol. 2012 May;7(5):571-5. NO ACCESS

  24. Basu S. The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: emphasis on PET-CT. Discov Med. 2012 Jan;13(68):65-73. Review. NO ACCESS

  25. Baudhuin LM, Donato LJ, Uphoff TS. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev Mol Diagn. 2012 Jan;12(1):25-37. doi: 10.1586/ERM.11.85. NO ACCESS

  26. Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012 May;42(3):190-207.

  27. Benichou J, Ben-Hamo R, Louzoun Y, Efroni S. Rep-Seq: uncovering the immunological repertoire through next-generation sequencing. Immunology. 2012 Mar;135(3):183-91. doi: 10.1111/j.1365-2567.2011.03527.x. Review.

  28. Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CD, Loda M. Investigative pathology: leading the post-genomic revolution. Lab Invest. 2012 Jan;92(1):4-8. doi: 10.1038/labinvest.2011.147.
  29. Bernet L, Martinez Benaclocha M, Castera C, Cano Muñoz R, Sevilla F, Alba J, de Dios Barranco J, Cordoba A, Garcia-Caballero T, Hardisson D, de Francisco Hernandez JM, Lazaro JM, Polo L, Riu F, Rezola R, Rojo F, Ruiz I, Hernándiz A, de la Cámara de Las Heras JM, Coupe VM. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study. Diagn Mol Pathol. 2012 Jun;21(2):84-92.

  30. Berry DA. Bayesian approaches for comparative effectiveness research. Clin Trials. 2012 Feb;9(1):37-47.

  31. Besse B, Soria JC. [Personalized medicine in oncology: from hope to reality]. Rev Prat. 2012 Feb;62(2):245-6. French.

  32. Black A, Morris D. Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol. 2012 Jun;19(Supplement 1):S73-S85.

  33. Blay JY, Lacombe D, Meunier F, Stupp R. Personalised medicine in oncology: questions for the next 20 years. Lancet Oncol. 2012 May;13(5):448-9.

  34. Bochud M, Fellmann F, Guessous I. [Are genetic tests useful for cardiovascular prevention?]. Rev Med Suisse. 2012 Mar 7;8(331):519-20, 522-4. French.

  35. Borrebaeck CA. Viewpoints in Clinical Proteomics - when will proteomics deliver clinically useful information? Proteomics Clin Appl. 2012 Jun 14. doi: 10.1002/prca.201200020. NO ACCESS

  36. Brüggenjürgen B, Kornbluth L, Ferrara JV, Willich SN. [Clinical and health economic challenges of personalized medicine]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 May;55(5):710-4. German.

  37. Braat H, Bruno M, Kuipers EJ, Peppelenbosch MP. Pancreatic cancer: promise for personalised medicine? Cancer Lett. 2012 May 1;318(1):1-8.
  38. Braun A, Halwachs B, Geier M, Weinhandl K, Guggemos M, Marienhagen J, Ruff AJ, Schwaneberg U, Rabin V, Torres Pazmiño DE, Thallinger GG, Glieder A. MuteinDB: the mutein database linking substrates, products and enzymatic reactions directly with genetic variants of enzymes. Database (Oxford). 2012 Jun 21;2012:bas028.

  39. Brenner MK. Personalized medicine: words that mean just what you choose? Mol Ther. 2012 Feb;20(2):241-2. doi: 10.1038/mt.2011.311.

  40. Brightling CE, Gupta S, Gonem S, Siddiqui S. Lung damage and airway remodelling in severe asthma. Clin Exp Allergy. 2012 May;42(5):638-49. doi: 10.1111/j.1365-2222.2011.03917.x.

  41. Brindle K. Watching tumours gasp and die with MRI: the promise of hyperpolarised 13C MR spectroscopic imaging. Br J Radiol. 2012 Jun;85(1014):697-708. Epub 2012 Apr 11. Review.

  42. Brown NJ. Patient-oriented research in the era of personalized medicine. Clin Transl Sci. 2012 Apr;5(2):119-20. doi: 10.1111/j.1752-8062.2011.00394.x. NO ACCESS

  43. Buckland M. Immunodeficiency: updating the personalized medicine approach to diagnostics and therapeutics. Expert Rev Clin Immunol. 2012 Mar;8(3):223-5.

  44. Buford TW, Pahor M. Making preventive medicine more personalized: Implications for exercise-related research. Prev Med. 2012 Jul;55(1):34-6.

  45. Burckart GJ, Green DJ. The personalized medicine revolution: Getting it right for children. Pediatr Transplant. 2012 Jan 9. doi: 10.1111/j.1399-3046.2011.01638.x.
  46. Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazana J, Hylands PJ. Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol. 2012 Apr 10;140(3):535-44.

  47. Buyx AM, Strech D, Schmidt H. [Ethical issues raised by direct-to-consumer personal genome analysis and whole body scans: discussion and contextualisation of a report by the Nuffield Council on Bioethics]. Z Evid Fortbild Qual Gesundhwes. 2012;106(1):29-39. German.

  48. Cantor CR. Company profile: Sequenom, Inc. Pharmacogenomics. 2012 Apr;13(5):529-31.

  49. Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2012 Mar;132(3 Pt 2):915-22. doi: 10.1038/jid.2011.395.

  50. Carlson B. In Search of the Perfect Business Model: As personalized medicine moves into the mainstream, makers of diagnostics must face a new economic reality. How to develop a value proposition in a healthcare market that is becoming increasingly elastic? Biotechnol Healthc. 2012 Spring;9(1):20-3.

  51. Carter CS, Barch DM; CNTRICS Executive Committee. Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development. Schizophr Bull. 2012 Jan;38(1):26-33.

  52. Carter RL, Chan AW. Pluripotent Stem Cells Models for Huntington's Disease: Prospects and Challenges. J Genet Genomics. 2012 Jun 20;39(6):253-9. NO ACCESS

  53. Caux C, Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Target Oncol. 2012 Mar;7(1):1-2. NO ACCESS
  54. Cecic IK, Li G, MacAulay C. Technologies supporting analytical cytology: clinical, research and drug discovery applications. J Biophotonics. 2012 Apr;5(4):313-26. doi: 10.1002/jbio.201100093. NO ACCESS

  55. Chae H, Lee S, Park SH, Jang E, Lee SJ. Development and validation of a personality assessment instrument for traditional korean medicine: sasang personality questionnaire. Evid Based Complement Alternat Med. 2012;2012:657013..

  56. Chang WY, Garcha K, Manias JL, Stanford WL. Deciphering the complexities of human diseases and disorders by coupling induced-pluripotent stem cells and systems genetics. Wiley Interdiscip Rev Syst Biol Med. 2012 Jul;4(4):339-50. doi: 10.1002/wsbm.1170.

  57. Chen C, Peng J, Sun SR, Peng CW, Li Y, Pang DW. Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Nanomedicine (Lond). 2012 Mar;7(3):411-28.

  58. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012 Mar 16;148(6):1293-307.

  59. Cheng CJ, Slack FJ. The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer. Cancer J. 2012 May;18(3):232-7. NO ACCESS
  60. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD, Zhang S. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012 Mar;25(3):347-69. doi: 10.1038/modpathol.2011.215. Epub 2012 Jan 27. Review. NO ACCESS

  61. Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol. 2012 Feb 25.

  62. Chiu PH, Hsieh HY, Wang SC. Prescriptions of traditional Chinese medicine are specific to cancer types and adjustable to temperature changes. PLoS One. 2012;7(2):e31648.

  63. Choi W, Jung H, Kim K, Lee S, Yoon S, Park J, Kim S, Cheon S, Eo W, Lee S. Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. J Biomed Biotechnol. 2012;2012:874276.

  64. Clancy JP, Jain M. Personalized Medicine in Cystic Fibrosis: Dawning of a New Era. Am J Respir Crit Care Med. 2012 Jun 21.

  65. Clausson CM, Grundberg I, Weibrecht I, Nilsson M, Söderberg O. Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments. EPMA J. 2012 Mar 22;3(1):7.

  66. Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam Clin Pharmacol. 2012 Feb;26(1):19-26. doi: 10.1111/j.1472-8206.2011.00983.x. Epub 2011 Aug 31. Review.

  67. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. 2012 Jan 10. doi: 10.1038/tpj.2011.63. NO ACCESS

  68. Collier R. A race-based detour to personalized medicine. CMAJ. 2012 Apr 17;184(7):E351-3.

  69. Corbacioglu S. Early phase clinical trials in pediatric hematology and oncology. Klin Padiatr. 2012 Apr;224(3):197-200. NO ACCESS
  70. Cordero F, Beccuti M, Donatelli S, Calogero RA. Large disclosing the nature of computational tools for the analysis of next generation sequencing data. Curr Top Med Chem. 2012 Jun 1;12(12):1320-30. NO ACCESS

  71. Cordero P, Ashley EA. Whole-Genome Sequencing in Personalized Therapeutics. Clin Pharmacol Ther. 2012 May 2. doi: 10.1038/clpt.2012.51

  72. Couch RD, Mott BT. Personalized medicine: changing the paradigm of drug development. Methods Mol Biol. 2012;823:367-78. NO ACCESS

  73. Cox AD, Der CJ. The RAF inhibitor paradox revisited. Cancer Cell. 2012 Feb 14;21(2):147-9.

  74. Cun Y, Fröhlich H. Prognostic gene signatures for patient stratification in breast cancer - accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions. BMC Bioinformatics. 2012 May 1;13(1):69.

  75. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012 Jun 15;26(12):1287-99. NO ACCESS

  76. Dammann M, Weber F. Personalized medicine: caught between hope, hype and the real world. Clinics (Sao Paulo). 2012;67 Suppl 1:91-7.

  77. Dancey J. Genomics, personalized medicine and cancer practice. Clin Biochem. 2012 Apr;45(6):379-81.

  78. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. NO ACCESS
  79. de Albuquerque A, Kaul S, Breier G, Krabisch P, Fersis N. Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine. Breast Care (Basel). 2012 Feb;7(1):7-12.

  80. de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012 Apr;32(2):153-64. NO ACCESS

  81. de Miranda DM, Mamede M, de Souza BR, de Almeida Barros AG, Magno LA, Alvim-Soares A Jr, Rosa DV, de Castro CJ Jr, Malloy-Diniz L, Gomez MV, De Marco LA, Correa H, Romano-Silva MA. Molecular medicine: a path towards a personalized medicine. Rev Bras Psiquiatr. 2012 Mar;34(1):82-91.

  82. De Velasco MA, Uemura H. Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol. 2012;2012:419348.

  83. Debergh I, Vanhove C, Ceelen W. Innovation in cancer imaging. Eur Surg Res. 2012;48(3):121-30. Epub 2012 Apr 24.

  84. Desiere F, Romano Spica V. Personalised Medicine in 2012: Editorial to the Special Issue of New Biotechnology on "MOLECULAR DIAGNOSTICS & PERSONALISED MEDICINE". N Biotechnol. 2012 Apr 5.

  85. Dhamne SA, Brown RE, Covinsky MH, Dhamne C, Eldin K, Tatevian N. Clear Cell Sarcoma of Kidney: Morphoproteomic Analysis Reveals Genomic Correlates and Therapeutic Options. Pediatr Dev Pathol. 2012 Jan 18. NO ACCESS

  86. Diaz FJ, Cogollo MR, Spina E, Santoro V, Rendon DM, de Leon J. Drug dosage individualization based on a random-effects linear model. J Biopharm Stat. 2012;22(3):463-84. NO ACCESS

  87. Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget. 2012 May;3(5):546-58.
  88. Drews K, Jozefczuk J, Prigione A, Adjaye J. Human induced pluripotent stem cells--from mechanisms to clinical applications. J Mol Med (Berl). 2012 Jul;90(7):735-45.

  89. Dry S, Grody WW, Papagni P. Stuck between a scalpel and a rock, or molecular pathology and legal-ethical issues in use of tissues for clinical care and research: what must a pathologist know? Am J Clin Pathol. 2012 Mar;137(3):346-55. Review.

  90. Dutton-Regester K, Hayward NK. Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res. 2012 Mar;25(2):144-54. doi: 10.1111/j.1755-148X.2012.00975.x.

  91. Eckhart AD, Beebe K, Milburn M. Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies. Clin Transl Sci. 2012 Jun;5(3):285-8. doi: 10.1111/j.1752-8062.2011.00388.x. NO ACCESS

  92. Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundström M, Micke P, Botling J, Soussi T. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9551-6.

  93. Eichler GS. Bioinformatics/biostatistics: microarray analysis. Methods Mol Biol. 2012;823:347-58. NO ACCESS

  94. Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD, Tanner SM, de la Chapelle A. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6668-73.
  95. Engel J, Emons G, Pinski J, Schally AV. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. NO ACCESS

  96. Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch Gynecol Obstet. 2012 Aug;286(2):437-42.

  97. Erickson HS. Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations. Stat Med. 2012 May 17. doi: 10.1002/sim.4485.

  98. Fahey JW, Talalay P, Kensler TW. Notes from the field: "green" chemoprevention as frugal medicine. Cancer Prev Res (Phila). 2012 Feb;5(2):179-88. Review. NO ACCESS

  99. Fan J, Deng X, Gallagher JW, Huang H, Huang Y, Wen J, Ferrari M, Shen H, Hu Y. Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Philos Transact A Math Phys Eng Sci. 2012 May 28;370(1967):2433-47.

  100. Farra N, Manickaraj AK, Ellis J, Mital S. Personalized Medicine in the Genomics Era: highlights from an international symposium on childhood heart disease. Future Cardiol. 2012 Mar;8(2):157-60.

  101. Feldman EA. The Genetic Information Nondiscrimination Act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med. 2012 Jun;27(6):743-6.

  102. Finn L, Tan W. Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. ISRN Oncol. 2012;2012:478607.

  103. Fleck LM. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. N Biotechnol. 2012 Mar 14.
  104. Floyd CN. Pharmacogenomic personalised medicine for antiplatelet agents is on the horizon. BMJ. 2012 Jun 19;344:e4198. doi: 10.1136/bmj.e4198

  105. Foran JM. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy. Hematology. 2012 Apr;17 Suppl 1:S137-40. NO ACCESS

  106. Formentini I, Bobadilla M, Haefliger C, Hartmann G, Loghman-Adham M, Mizrahi J, Pomposiello S, Prunotto M, Meier M. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol Dial Transplant. 2012 Jun 25.

  107. Frank E, Kupfer DJ, Rucci P, Lotz-Wallace M, Levenson J, Fournier J, Kraemer HC. Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach. Psychol Med. 2012 Apr;42(4):865-73.

  108. Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. Stat Med. 2012 Aug 3. doi: 10.1002/sim.5541.

  109. Frueh FW. On rat poison and human medicines: personalizing warfarin therapy. Trends Mol Med. 2012 Apr;18(4):201-5.

  110. Fueldner C, Mittag A, Knauer J, Biskop M, Hepp P, Scholz R, Wagner U, Sack U, Emmrich F, Tárnok A, Lehmann J. Identification and evaluation of novel synovial tissue biomarkers in rheumatoid arthritis by laser scanning cytometry. Arthritis Res Ther. 2012 Jan 17;14(1):R8.

  111. Galetta D, Rossi A, Pisconti S, Colucci G. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S45-54. NO ACCESS
  112. Gandhi L, Jänne PA. Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target. Clin Cancer Res. 2012 Jun 21.

  113. Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012 Mar;2(3):214-26 NO ACCESS

  114. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8;366(10):883-92.
  115. Gespach C. Guidance for life, cell death, and colorectal neoplasia by netrin dependence receptors. Adv Cancer Res. 2012;114:87-186.

    Share with your friends:
  1   2   3   4   5   6   7   8   9   ...   12

The database is protected by copyright © 2019
send message

    Main page